Rodman & Renshaw Begins Coverage on Telomir Pharmaceuticals (NASDAQ:TELO)

Rodman & Renshaw began coverage on shares of Telomir Pharmaceuticals (NASDAQ:TELO) in a report issued on Friday morning, MarketBeat reports. The brokerage issued a buy rating and a $15.00 price target on the stock.

Telomir Pharmaceuticals Price Performance

Shares of TELO stock opened at $3.91 on Friday. Telomir Pharmaceuticals has a 12-month low of $3.11 and a 12-month high of $9.54. The business has a 50 day simple moving average of $4.56 and a 200 day simple moving average of $4.85.

Telomir Pharmaceuticals (NASDAQ:TELO) last released its quarterly earnings results on Tuesday, February 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.05). Equities research analysts anticipate that Telomir Pharmaceuticals will post -0.4 EPS for the current year.

Hedge Funds Weigh In On Telomir Pharmaceuticals

Large investors have recently bought and sold shares of the stock. State Street Corp lifted its stake in shares of Telomir Pharmaceuticals by 99.1% in the 3rd quarter. State Street Corp now owns 36,094 shares of the company’s stock worth $232,000 after acquiring an additional 17,967 shares during the period. Barclays PLC lifted its position in Telomir Pharmaceuticals by 325.1% in the third quarter. Barclays PLC now owns 7,018 shares of the company’s stock worth $45,000 after purchasing an additional 5,367 shares during the period. Geode Capital Management LLC increased its position in shares of Telomir Pharmaceuticals by 259.8% during the 3rd quarter. Geode Capital Management LLC now owns 238,737 shares of the company’s stock valued at $1,533,000 after purchasing an additional 172,382 shares during the period. Rhumbline Advisers lifted its holdings in shares of Telomir Pharmaceuticals by 105.9% in the fourth quarter. Rhumbline Advisers now owns 8,600 shares of the company’s stock valued at $35,000 after buying an additional 4,424 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in Telomir Pharmaceuticals by 40.8% during the fourth quarter. Bank of New York Mellon Corp now owns 72,295 shares of the company’s stock valued at $298,000 after buying an additional 20,931 shares in the last quarter.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.